Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma

Press/Media: Press / Media

PeriodNov 6 2019

Media coverage

11

Media coverage

  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletGlobal English (Middle East and North Africa Financial Network)
    CountryJordan
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletStocksNewsFeed.com
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitlePublication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletMarket News Publishing
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitlePublication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletMarket News Publishing
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletIT Business Net
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleONCOLYTICS BIOTECH : R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletMarketScreener.com
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletCrwe World
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletFSCwire
    CountryCanada
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletOncolytics Biotech
    CountryCanada
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletFinanzNachrichten.de
    CountryGermany
    Date11/6/19
    PersonsDevalingam Mahalingam
  • TitleOncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
    Media name/outletTulsa CW
    CountryUnited States
    Date11/6/19
    PersonsDevalingam Mahalingam